AU Patent

AU2016219102B2 — LRRK2 inhibitors and methods of making and using the same

Assigned to Dana Farber Cancer Institute Inc · Expires 2020-10-15 · 6y expired

What this patent protects

Compounds having the formula (I), (II), (III) are provided. Compounds of the present disclosure are useful for the treatment of neurodegenerative diseases, such as Parkinson's Disease.

USPTO Abstract

Compounds having the formula (I), (II), (III) are provided. Compounds of the present disclosure are useful for the treatment of neurodegenerative diseases, such as Parkinson's Disease.

Drugs covered by this patent

Patent Metadata

Patent number
AU2016219102B2
Jurisdiction
AU
Classification
—
Expires
2020-10-15
Drug substance claim
No
Drug product claim
No
Assignee
Dana Farber Cancer Institute Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.